The Estrogen Black Box Warning Is Gone: Why I'm So Excited

Last week, I got to meet Dr. Rachel Rubin in person, and I'm still a little starstruck! If you haven't heard of her, she's a urologist and sexual medicine specialist, and she was one of the clearest voices pushing the FDA to remove the estrogen black box warning from menopausal hormone therapy. That label shaped how a whole generation of women (and their doctors) thought about estrogen, and it's something I talk about in clinic all the time. So let's walk through what changed and why I'm so excited about it.

What was the estrogen black box warning, and what changed?

A black box warning, also called a boxed warning, is the strongest warning the FDA puts on a drug label. Since 2003, estrogen products carried one that warned about heart disease, stroke, breast cancer, and probable dementia, and told prescribers to use "the lowest effective dose for the shortest duration." It went on everything, including the low-dose vaginal creams, tablets, and rings that barely reach the bloodstream.

On November 10, 2025, the FDA announced it would remove those warnings [1], and it approved the first batch of updated labels on February 12, 2026 [2]. The new labels:

• Drop the boxed warnings about heart disease, stroke, breast cancer, and probable dementia

• Drop the "lowest dose, shortest time" instruction, so you and your doctor can make an individual plan

• Add guidance that starting systemic hormone therapy before age 60, or within 10 years of menopause, gives the best balance of benefit and risk

• Keep one boxed warning: estrogen taken alone raises the risk of endometrial (uterine) cancer in someone who still has a uterus, which is why those women also take a progestogen

At the FDA's expert panel in July 2025, Dr. Rubin summed it up perfectly: "Science evolves and so must our warning labels" [3].

Why did one label scare so many women away?

The warning came out of the Women's Health Initiative, a huge study whose early results made headlines in 2002. What didn't make the headlines is that the women in it were, on average, in their early 60s, many of them more than a decade past menopause. Later analyses showed that age and timing change the picture a lot [4].

But the fear stuck. I've had patients tell me they were scared to even fill a prescription for vaginal estrogen after reading the insert, and I completely understand why. When the strongest warning the FDA has is printed on the box, it's hard to believe the risk is small.

What does vaginal estrogen have to do with your pelvic floor?

This is the part I get most excited about. The tissues of the vulva, vagina, urethra, and bladder all depend on estrogen. When estrogen drops in perimenopause and menopause, those tissues can get thinner, drier, and more irritable. The medical name for this is genitourinary syndrome of menopause, or GSM, and it can show up as:

• Dryness, burning, or itching

• Pain with sex

• Urgency, or needing to pee all the time

• Urinary tract infections that keep coming back

• Increase in stress urinary incontinence

The 2025 guideline from the American Urological Association and two urogynecology societies, which Dr. Rubin helped write, recommends vaginal estrogen to treat GSM symptoms and to cut down on recurrent UTIs [5]. This isn't new science, either. A trial back in 1993 found that women using vaginal estriol had about 0.5 UTIs per year, compared with 5.9 in the placebo group [6]. More recently, a large records study found that postmenopausal women with recurrent UTIs who used vaginal estrogen had sepsis about half as often (10.6% vs. 19.4%) and a lower death rate than women who didn't [7]. That study can't prove cause and effect, but when a UTI can turn into urosepsis for an older woman, those numbers matter.

In my practice, I see this overlap constantly. A woman comes in with urgency or pain with sex, and we do great work calming down a tight pelvic floor, but the tissue itself is still thin and sore. Pelvic floor therapy can retrain the muscles, and it can't replace the estrogen those tissues are missing. Often the best results come from doing both, with your doctor handling the prescription side and me handling the muscle side.

Does estrogen cause breast cancer?

This is the question everyone asks, and I want to give you an honest answer rather than a slogan. For systemic hormone therapy, the risk depends on the type of hormones, your age, how long you take them, and your own history, so that is a real conversation to have with your doctor.

For vaginal estrogen, the news is reassuring. A study of 49,237 women with breast cancer in Scotland and Wales found that women who used vaginal estrogen after their diagnosis did not have a higher risk of dying from breast cancer, and their risk was actually a bit lower [8]. You may hear that described as "estrogen helps survivors live longer," and I'd love for that to be true! But the authors themselves concluded only that there was "no evidence of increased" risk, because women who get vaginal estrogen may be different in other ways that the study couldn't measure. What I feel confident telling you is that the old fear deserves a second look, and if you're a survivor with GSM symptoms, it's absolutely worth raising with your oncologist.

What about your bones, heart, and brain?

The Menopause Society's position is that for women under 60, or within 10 years of menopause, the benefits of hormone therapy generally outweigh the risks for hot flashes and for preventing bone loss and fractures [4]. That bone piece is a big deal for the women I see, because a fracture can change everything about how you move.

The heart and brain story also comes back to timing. The "probable dementia" warning came from women who started hormones at 65 or older, and starting closer to menopause appears to carry less cardiovascular risk than starting later [4]. Hormone therapy isn't recommended as a way to prevent dementia, and the research on heart protection is still being sorted out, so think of these as reasons to have the conversation sooner rather than as promises.

So should you start estrogen?

That's not my call, and it shouldn't be a blog's call either. I'm a physical therapist, and I don't prescribe hormones. I can tell you I myself am confidently on hormones, with the guidance and support of my doctor. And I can help you walk into your appointment with better questions:

• Could my dryness, pain with sex, urgency, or repeat UTIs be GSM?

• Is vaginal estrogen an option for me, given my history?

• If I'm under 60 or within 10 years of menopause, does systemic hormone therapy make sense for me?

• If I've had breast cancer, can we talk with my oncologist about vaginal estrogen?

If your doctor isn't comfortable with these questions, The Menopause Society has a directory of certified menopause practitioners, and you deserve someone who will dig in with you.

If pain with sex is part of your story, my post on why painful sex happens and what actually helps is a good next read. If it's more about running to the bathroom, start with overactive bladder or what incontinence treatment actually looks like.

You don't have to just live with it

I left that weekend feeling so hopeful. For years, a lot of women were told that dryness, painful sex, and constant UTIs were just part of getting older, and the label made it harder to get help. That's finally changing, and I'd love to be part of your team as you figure out what's right for you.

You can reach Protea Physical Therapy at (909) 265-3584, and I see patients here in Anaheim Hills, serving Orange County. If you'd like to talk it through first, book a free 15-minute discovery call.

This article is for education only and is not medical advice. Hormone therapy is a prescription decision, so please talk with your doctor about your own symptoms and history.

References

1. Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. FDA labeling changes for menopausal hormone therapy. JAMA. Published online November 10, 2025. doi:10.1001/jama.2025.22259. https://jamanetwork.com/journals/jama/fullarticle/2841321

2. Clarke H. FDA approves label changes for first batch of menopausal hormone therapy products. Urology Times. February 12, 2026. https://www.urologytimes.com/view/fda-approves-label-changes-for-first-batch-of-menopausal-hormone-therapy-products

3. Clarke H. Experts urge FDA to remove black box warning on low-dose vaginal estrogen. Urology Times. July 18, 2025. https://www.urologytimes.com/view/experts-urge-fda-to-remove-black-box-warning-on-low-dose-vaginal-estrogen

4. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf

5. Kaufman MR, Ackerman AL, Amin KA, et al. The AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause. J Urol. 2025;214(3):242-250. https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause

6. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756. https://www.nejm.org/doi/full/10.1056/NEJM199309093291102

7. Wells B, Visingardi J, Feustel P, De E. Impact of vaginal estrogen on serious adverse outcomes in postmenopausal women with recurrent urinary tract infections: a retrospective study. International Continence Society 2025, Abstract 118. https://www.ics.org/2025/abstract/118

8. McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-108. doi:10.1001/jamaoncol.2023.4508. https://jamanetwork.com/journals/jamaoncology/fullarticle/2811413